Cellular interactions in the pathogenesis of interstitial lung diseases

European Respiratory Review

Volumn 24, Issue 135, 2015, Pages 102-114

  Bagnato, Gianluca ^a   Harari, Sergio ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ANTIBODY PRODUCTION; APOPTOSIS; BLOOD VESSEL INJURY; CELL INTERACTION; CELLS BY BODY ANATOMY; CELLULAR DISTRIBUTION; EFFECTOR CELL; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; FIBROCYTE; FIBROGENESIS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS EPITHELIUM CELL; LUNG FIBROSIS; LUNG INFILTRATE; MACROPHAGE ACTIVATION; MAST CELL; MESOTHELIUM CELL; MONOCYTE; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PERICYTE; POLYMORPHONUCLEAR CELL; REVIEW; TH2 CELL; CELL COMMUNICATION; CYTOLOGY; ENDOTHELIAL PROGENITOR CELL; EPITHELIUM CELL; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE; MESODERM; NEUTROPHIL; PATHOLOGY; PHYSIOLOGY;

ANTIBODY FORMATION; APOPTOSIS; CELL COMMUNICATION; ENDOTHELIAL CELLS; ENDOTHELIAL PROGENITOR CELLS; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTES; MAST CELLS; MESODERM; MONOCYTES; MYOFIBROBLASTS; NEUTROPHILS; PERICYTES; TH2 CELLS;

EID: 84923882858     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00003214     Document Type: Review

References (135)

1. Cottin V. Interstitial lung disease. Eur Respir Rev 2013; 22: 26–32.
2. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
3. Lederer DJ. Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward. Eur Respir J 2013; 42: 1446–1448.
4. Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801–809.
5. Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy 2010; 65: 537–553.
6. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66: 940–944.
7. Cottin V. Significance of connective tissue diseases features in pulmonary fibrosis. Eur Respir Rev 2013; 22: 273–280.
8. Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2013; 41: 1207–1218.
9. Kramann R, DiRocco DP, Humphreys BD. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J Pathol 2013; 231: 273–289.
10. Enomoto N, Suda T, Kato M, et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest 2006; 130: 22–29.
11. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557–567.
12. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807–1816.
13. Castella LF, Buscemi L, Godbout C, et al. A new lock-step mechanism of matrix remodelling based on subcellular contractile events. J Cell Sci 2010; 123: 1751–1760.
14. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349–363.
15. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002; 122: Suppl. 6, 286S–289S.
16. Chang HY, Chi JT, Dudoit S, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002; 99: 12877–12882.
17. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63: 783–794.
18. Ruiz XD, Mlakar LR, Yamaguchi Y, et al. Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis. PLoS One 2012; 7: e43049.
19. Fang F, Ooka K, Bhattacharyya S, et al. The early growth response gene Egr2 (alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol 2011; 178: 2077–2090.
20. Yasuoka H, Hsu E, Ruiz XD, et al. The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms. Am J Pathol 2009; 175: 605–615.
21. Bhattacharyya S, Wu M, Fang F, et al. Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol 2011; 30: 235–242.
22. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3: 350–356.
23. Drakopanagiotakis F, Xifteri A, Polychronopoulos V, et al. Apoptosis in lung injury and fibrosis. Eur Respir J 2008; 32: 1631–1638.
24. Nho RS, Peterson M, Hergert P, et al. FoxO3a (Forkhead Box O3a) deficiency protects idiopathic pulmonary fibrosis (IPF) fibroblasts from type I polymerized collagen matrix-induced apoptosis via caveolin-1 (cav-1) and Fas. PLoS One 2013; 8: e61017.
25. Del Galdo F, Sotgia F, de Almeida CJ, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58: 2854–2865.
26. Raghu G, Chen YY, Rusch V, et al. Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. Am Rev Respir Dis 1988; 138: 703–708.
27. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286–1292.
28. Mimura Y, Ihn H, Jinnin M, et al. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol 2005; 124: 886–892.
29. Kinoshita K, Aono Y, Azuma M, et al. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 2013; 49: 536–543.
30. Königshoff M, Balsara N, Pfaff EM, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008; 3: e2142.
31. Lam AP, Flozak AS, Russell S, et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol 2011; 45: 915–922.
32. Sun Z, Gong X, Zhu H, et al. Inhibition of Wnt/β-catenin signaling promotes engraftment of mesenchymal stem cells to repair lung injury. J Cell Physiol 2014; 229: 213–224.
33. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976–985.
34. Bucala R, Spiegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71–81.
35. Moore BB, Kolodsick JE, Thannickal VJ, et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005; 166: 675–684.
36. Strieter RM, Keeley EC, Hughes MA, et al. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009; 86: 1111–1118.
37. Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010; 90: 812–823.
38. Borie R, Quesnel C, Phin S, et al. Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis. PLoS One 2013; 8: e53736.
39. Andersson-Sjöland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40: 2129–2140.
40. Maharaj S, Shimbori C, Kolb M. Fibrocytes in pulmonary fibrosis: a brief synopsis. Eur Respir Rev 2013; 22: 552–557.
41. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95: 1861–1868.
42. Günther A, Korfei M, Mahavadi P, et al. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 152–160.
43. Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181: 254–263.
44. van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med 2010; 182: 1419–1425.
45. Kim KK, Wei Y, Szekeres C, et al. Epithelial cell α3β1 integrin links β-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 2009; 119: 213–224.
46. Marmai C, Sutherland RE, Kim KK, et al. Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2011; 301: L71–L78.
47. Rock JR, Barkauskas CE, Cronce MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 2011; 108: E1475–E1483.
48. Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008; 177: 56–65.
49. Wygrecka M, Didiasova M, Berscheid S, et al. Protease-activated receptors (PAR)-1 and -3 drive epithelial-mesenchymal transition of alveolar epithelial cells–potential role in lung fibrosis. Thromb Haemost 2013; 110: 295–307.
50. Manetti M, Rosa I, Milia AF, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 2014; 73: 1700–1709.
51. Bauman KA, Wettlaufer SH, Okunishi K, et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 2010; 120: 1950–1960.
52. Shukla MN, Rose JL, Ray R, et al. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am J Respir Cell Mol Biol 2009; 40: 643–653.
53. Mizuno S, Matsumoto K, Li MY, et al. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005; 19: 580–582.
54. Kawaguchi Y, Harigai M, Fukasawa C, et al. Increased levels of hepatocyte growth factor in sera of patients with systemic sclerosis. J Rheumatol 1999; 26: 1012–1013.
55. Marchand-Adam S, Fabre A, Mailleux AA, et al. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 58–66.
56. Funke M, Zhao Z, Xu Y, et al. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol 2012; 46: 355–364.
57. Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14: 45–54.
58. Tokumura A, Carbone LD, Yoshioka Y, et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009; 6: 168–176.
59. Torres-González E, Bueno M, Tanaka A, et al. Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis. Am J Respir Cell Mol Biol 2012; 46: 748–756.
60. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16: 534–554.
61. Bagnato G, Bitto A, Pizzino G, et al. Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis. Rheumatology 2013; 52: 1377–1386.
62. Kliment CR, Oury TD. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 2010; 49: 707–717.
63. Gabrielli A, Svegliati S, Moroncini G, et al. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J 2012; 6: 87–95.
64. Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 2010; 6: 453–460.
65. Ren Y, Guo L, Tang X, et al. Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells. Microvasc Res 2013; 85: 59–67.
66. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203–1208.
67. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004; 170: 242–251.
68. Hall SM, Hislop AA, Pierce CM, et al. Prenatal origins of human intrapulmonary arteries: formation and smooth muscle maturation. Am J Respir Cell Mol Biol 2000; 23: 194–203.
69. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362–367.
70. Malli F, Koutsokera A, Paraskeva E, et al. Endothelial progenitor cells in the pathogenesis of idiopathic pulmonary fibrosis: an evolving concept. PLoS One 2013; 8: e53658.
71. Zhu S, Evans S, Yan B, et al. Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. Circulation 2008; 118: 2156–2165.
72. Avouac J, Juin F, Wipff J, et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 2008; 67: 1455–1460.
73. Del Papa N, Quirici N, Soligo D, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006; 54: 2605–2615.
74. Li Z, Jimenez SA. Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum 2011; 63: 2473–2483.
75. Hashimoto N, Phan SH, Imaizumi K, et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010; 43: 161–172.
76. Armulik A, Genové G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21: 193–215.
77. Sundberg C, Ivarsson M, Gerdin B, et al. Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest 1996; 74: 452–466.
78. Schmitt-Gräff A, Krüger S, Bochard F, et al. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol 1991; 138: 1233–1242.
79. Adler KB, Callahan LM, Evans JN. Cellular alterations in the alveolar wall in bleomycin-induced pulmonary fibrosis in rats. An ultrastructural morphometric study. Am Rev Respir Dis 1986; 133: 1043–1048.
80. Mahoney WM Jr, Fleming JN, Schwartz SM. A unifying hypothesis for scleroderma: identifying a target cell for scleroderma. Curr Rheumatol Rep 2011; 13: 28–36.
81. Nasreen N, Mohammed KA, Mubarak KK, et al. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-β1 in vitro. Am J Physiol Lung Cell Mol Physiol 2009; 297: L115–L124.
82. Zolak JS, Jagirdar R, Surolia R, et al. Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury. Am J Pathol 2013; 182: 1239–1247.
83. Mubarak KK, Montes-Worboys A, Regev D, et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 133–140.
84. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144: 706–713.
85. Lohmann-Matthes ML, Steinmüller C, Franke-Ullmann G. Pulmonary macrophages. Eur Respir J 1994; 7: 1678–1689.
86. Capelli A, Di Stefano A, Gnemmi I, et al. CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis. Eur Respir J 2005; 25: 701–707.
87. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 7303–7311.
88. Prasse A, Pechkovsky DV, Toews GB, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006; 173: 781–792.
89. Bergeron A, Soler P, Kambouchner M, et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-β and IL-10. Eur Respir J 2003; 22: 69–76.
90. Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010; 5: e9683.
91. Homer RJ, Herzog EL. Recent advances in pulmonary fibrosis: implications for scleroderma. Curr Opin Rheumatol 2010; 22: 683–689.
92. Homer RJ, Elias JA, Lee CG, et al. Modern concepts on the role of inflammation in pulmonary fibrosis. Arch Pathol Lab Med 2011; 135: 780–788.
93. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173–1179.
94. Trujillo G, Meneghin A, Flaherty KR, et al. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2010; 2: 57ra82.
95. Khalil N, Bereznay O, Sporn M, et al. Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med 1989; 170: 727–737.
96. Kiemle-Kallee J, Kreipe H, Radzun HJ, et al. Alveolar macrophages in idiopathic pulmonary fibrosis display a more monocyte-like immunophenotype and an increased release of free oxygen radicals. Eur Respir J 1991; 4: 400–406.
97. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008; 20: 707–712.
98. O’Reilly S, Hügle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology 2012; 51: 1540–1549.
99. Belperio JA, Dy M, Murray L, et al. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol 2004; 173: 4692–4698.
100. Shimizu S, Yoshinouchi T, Niimi T, et al. Differing distributions of CXCR3- and CCR4-positive cells among types of interstitial pneumonia associated with collagen vascular diseases. Virchows Arch 2007; 450: 51–58.
101. Rottoli P, Magi B, Perari MG, et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005; 5: 1423–1430.
102. Luzina IG, Todd NW, Nacu N, et al. Regulation of pulmonary inflammation and fibrosis through expression of integrins αVβ3 and αVβ5 on pulmonary T lymphocytes. Arthritis Rheum 2009; 60: 1530–1539.
103. Kotsianidis I, Nakou E, Bouchliou I, et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1121–1130.
104. Slobodin G, Ahmad MS, Rosner I, et al. Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlate with disease activity and severity. Cell Immunol 2010; 261: 77–80.
105. Truchetet ME, Brembilla NC, Montanari E, et al. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011; 13: R166.
106. Hasegawa M, Fujimoto M, Takehara K, et al. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 2005; 39: 1–7.
107. Xue J, Kass DJ, Bon J, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol 2013; 191: 2089–2095.
108. Yoshizaki A, Yanaba K, Ogawa A, et al. Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011; 63: 3575–3585.
109. De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40: 435–446.
110. Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 2008; 181: 7243–7253.
111. Ostojic P, Cerinic MM, Silver R, et al. Interstitial lung disease in systemic sclerosis. Lung 2007; 185: 211–220.
112. Magro CM, Ross P, Marsh CB, et al. The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol 2007; 127: 237–247.
113. Fineschi S, Goffin L, Rezzonico R, et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008; 58: 3913–3923.
114. Hasegawa M, Sato S, Yanaba K, et al. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 2004; 63: 1514–1517.
115. Meliconi R, Bestagno M, Sturani C, et al. Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease. Clin Exp Immunol 1989; 76: 184–189.
116. Au K, Khanna D, Clements PJ, et al. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 2009; 11: 111–119.
117. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010; 49: 271–280.
118. Domagała-Kulawik J, Hoser G, Doboszyńska A, et al. Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocyte phenotype and DLCO impairment. Respir Med 1998; 92: 1295–1301.
119. Esposito I, Perna F, Ponticiello A, et al. Natural killer cells in BAL and peripheral blood of patients with idiopathic pulmonary fibrosis (IPF). Int J Immunopathol Pharmacol 2005; 18: 541–545.
120. Overed-Sayer C, Rapley L, Mustelin T, et al. Are mast cells instrumental for fibrotic diseases? Front Pharmacol 2014; 4: 174.
121. Heard BE, Dewar A, Corrin B. Apposition of fibroblasts to mast cells and lymphocytes in normal human lung and in cryptogenic fibrosing alveolitis. Ultrastructure and cell perimeter measurements. J Pathol 1992; 166: 303–310.
122. Andersson CK, Mori M, Bjermer L, et al. Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 206–217.
123. Wygrecka M, Dahal BK, Kosanovic D, et al. Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-α/Raf-1/p44/42 signaling pathway. Am J Pathol 2013; 182: 2094–2108.
124. Mori H, Kawada K, Zhang P, et al. Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int Arch Allergy Appl Immunol 1991; 95: 195–201.
125. Cha SI, Chang CS, Kim EK, et al. Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis. Histopathology 2012; 61: 98–106.
126. Hunninghake GW, Gadek JE, Lawley TJ, et al. Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1981; 68: 259–269.
127. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007; 30: 835–839.
128. Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133: 226–232.
129. Meloni F, Caporali R, Marone Bianco A, et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 111–118.
130. Boomars KA, Wagenaar SS, Mulder PG, et al. Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax 1995; 50: 1087–1092.
131. Cailes JB, O’Connor C, Pantelidis P, et al. Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis. Eur Respir J 1996; 9: 992–999.
132. Prasse A, Pechkovsky DV, Toews GB, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007; 56: 1685–1693.
133. Takemasa A, Ishii Y, Fukuda T. A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2012; 40: 1475–1482.
134. Cappelli S, Guiducci S, Bellando Randone S, et al. Immunosuppression for interstitial lung disease in systemic sclerosis. Eur Respir Rev 2013; 22: 236–243.
135. Selimović S, Dokmeci MR, Khademhosseini A. Organs-on-a-chip for drug discovery. Curr Opin Pharmacol 2013; 13: 829–833.